Peter Ruf

Title: Peter Ruf - Innovator in Tumor Immunization

Introduction

Peter Ruf is a notable inventor residing in Schoengeising, Germany. He has made a significant contribution to the field of biotechnology through his innovative work in immunization techniques. His research focuses on the time-staggered utilization of tumor cells, aimed at enhancing the efficacy of immunization in both humans and animals.

Latest Patents

Peter Ruf holds one patent entitled "Time-staggered utilization of tumor cells in combination with intact antibodies for immunization." This invention addresses the innovative application of tumor cells in immunization processes, specifically through the use of intact, preferably heterologous antibodies. The approach aims to improve the therapeutic outcomes for patients and has implications for both veterinary and human medicine.

Career Highlights

Peter Ruf is currently employed at Trion Pharma GmbH, a company known for its pioneering work in biopharmaceuticals. His role entails extensive research and development efforts aimed at advancing immunotherapy techniques. Throughout his career, Ruf has demonstrated a commitment to improving treatment strategies for oncology patients.

Collaborations

One of Peter Ruf's key collaborators is Horst Lindhofer. Together, they have synergized their expertise to explore novel methods for tumor immunization. Their partnership is a testament to the innovative spirit and dedication present within the field of biomedical research.

Conclusion

Peter Ruf stands out as an influential inventor in the realm of immunology and oncology. His pioneering patent on tumor cell utilization showcases his dedication to enhancing health outcomes through innovation. As he continues his work at Trion Pharma GmbH, the impact of his contributions may lead to significant advancements in immunization strategies, ultimately benefiting both human and animal health.